YanagimotoYMinowaKYoshidaE, et al.Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: a retrospective study. Lupus2025. [In Press]. DOI: 10.1177/09612033251401641.
2.
AyanoMHirataATokunagaS, et al.No clear influence of treatment escalation on flare prevention in serologically active clinically quiescent patients with systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int2024; 44(11): 2411–2419.
3.
DingYZhouYZhanF, et al.Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: a cluster analysis based on CSTAR cohort. Méd Sur2024; 5(10): 1266–1274.e3.
4.
AnNChenHTDengWB, et al.Short-term incremental prednisone therapy in patients with serologically active clinically quiescent lupus nephritis: a retrospective observational study. Eur J Med Res2024; 29(1): 555.
5.
KatsumataYInoueEHarigaiM, et al.Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis2024; 83(8): 998–1005.
6.
NiyompanichakarnSChaiamnuaySNarongroeknawinP, et al.The effect of gradual withdrawal versus maintenance of low-dose glucocorticoid in clinically quiescent systemic lupus erythematosus, a pilot double-blind randomised controlled trial. Muscoskel Care2025; 23(2): e70083.
7.
HuangHMuLZhangZ, et al.Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther2021; 23(1): 275.
